KOD News and Press, Kodiak Sciences Inc From 02/23/22

Stocks recorded another day of losses on Wednesday, weighed down by continued worries about tension with Russia and lingering fear about rising interest rates. The Nasdaq led the decline with a slide of 2.6%, as speculative names saw the most aggressive selling.  Meanwhile, the S&P 5...

Shares of the clinical-stage biotech Kodiak Sciences (NASDAQ: KOD) are down by a hefty 80.3% as of 2:22 p.m. ET Wednesday afternoon. The drugmaker's stock is plunging today in response to its lead product candidate, KSI-301, failing to meet the primary endpoint of a combined phase 2...

Kodiak Sciences (KOD -79.8%), a clinical-stage biotech focused on eye diseases, has lost more than $2B of its market capitalization on Wednesday after the company said its lead asset KSI-301 did not meet the primary endpoint in a Phase 2b/3 trial for wet age-related macular degeneration. The ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today,  Kodiak Sciences (NASDAQ: KOD ) has posted one of the worst single-day losses I’ve seen in some time. Currently, KOD stock is down more than 80%, losing four-fifths of its value in a single day. S...

Kodiak Sciences (KOD -79.8%), a clinical-stage biotech focused on eye diseases, has lost more than $2B of its market capitalization on Wednesday after the company said its lead asset KSI-301 did not meet the primary endpoint in a Phase 2b/3 trial for wet age-related macular degeneration. The ...

Gainers: Revelation Biosciences REVB +29%. Mainz Biomed MYNZ +9%. Relmada Therapeutics (NASDAQ:RLMD) +9%. Panbela Therapeutics (NASDAQ:PBLA) +7%. Pyxis Oncology (NASDAQ:PYXS) +4%. Losers: Kodiak Sciences KOD -78%. Ocugen OCGN -20%. R...

Kodiak Sciences's (NASDAQ:KOD) medicine KSI-301 failed to meet the main goal of a phase 2b/3 trial in patients with neovascular (wet) age-related macular degeneration who had not received prior treatment. Wet macular degeneration is a chronic eye disorder that causes blurred vision and c...

Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration - The study did not meet the primary endpoint of showing non-inferior visual acuity gains compared to aflibercept given eve...

KSI-301 has shown higher retinal bioavailability and longer half-life than the comparator for this Phase 3 trial, the blockbuster drug Eylea (Aflibercept). Kodiak is attempting to prove non-inferiority in efficacy as shown by BCVA at 1 year vs. Eylea while showing the advantage of les...

Kodiak Sciences (NASDAQ:KOD) completed enrollment in its GLEAM and GLIMMER phase 3 trials of KSI-301 in patients with diabetic macular edema (DME). "We are very pleased to have completed enrollment in our GLEAM and GLIMMER pivotal trials, where we are studying KSI-301's potenti...